Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roxane Orlaam Discontinued; Suboxone Approval Cited As Reason

Executive Summary

The availability of Reckitt Benckiser's anti-addiction agent Suboxone is one factor prompting Roxane Laboratories to discontinue production of Orlaam

You may also be interested in...



FDA Drug Withdrawal Rate In Post-User Fee Era Higher Than Pre-PDUFA

The rate of drug withdrawals due to safety concerns since FDA started collecting user fees has crept past the pre-user fee rate, the Center for Drug Evaluation & Research says in its "FDL-12004 Report to the Nation.

FDA Drug Withdrawal Rate In Post-User Fee Era Higher Than Pre-PDUFA

The rate of drug withdrawals due to safety concerns since FDA started collecting user fees has crept past the pre-user fee rate, the Center for Drug Evaluation & Research says in its "FDL-12004 Report to the Nation.

Subutex/Suboxone Prescriber Registration Efforts Ramping Up After Approval

The Substance Abuse & Mental Health Services Administration is working to register physicians to prescribe Schering-Plough/Reckitt Benckiser's opioid addiction treatment therapies Subutex and Suboxone in advance of the products' launch

UsernamePublicRestriction

Register

LL1135415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel